GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Beneish M-Score

Huakang Biomedical Holdings Co (HKSE:08622) Beneish M-Score : -3.36 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.36 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Huakang Biomedical Holdings Co's Beneish M-Score or its related term are showing as below:

HKSE:08622' s Beneish M-Score Range Over the Past 10 Years
Min: -3.52   Med: -2.53   Max: -2.24
Current: -3.36

During the past 9 years, the highest Beneish M-Score of Huakang Biomedical Holdings Co was -2.24. The lowest was -3.52. And the median was -2.53.


Huakang Biomedical Holdings Co Beneish M-Score Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Beneish M-Score Chart

Huakang Biomedical Holdings Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -2.24 -3.07 -2.32 -2.43 -3.36

Huakang Biomedical Holdings Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -3.36 -

Competitive Comparison of Huakang Biomedical Holdings Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Huakang Biomedical Holdings Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huakang Biomedical Holdings Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huakang Biomedical Holdings Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Huakang Biomedical Holdings Co's Beneish M-Score falls into.



Huakang Biomedical Holdings Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Huakang Biomedical Holdings Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9216+0.528 * 1.022+0.404 * 0.4605+0.892 * 0.9524+0.115 * 1.1189
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.014+4.679 * -0.08778-0.327 * 1.4745
=-3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$15.03 Mil.
Revenue was HK$26.94 Mil.
Gross Profit was HK$17.60 Mil.
Total Current Assets was HK$58.45 Mil.
Total Assets was HK$71.44 Mil.
Property, Plant and Equipment(Net PPE) was HK$10.66 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$3.48 Mil.
Selling, General, & Admin. Expense(SGA) was HK$20.23 Mil.
Total Current Liabilities was HK$14.32 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1.29 Mil.
Net Income was HK$-6.32 Mil.
Gross Profit was HK$0.00 Mil.
Cash Flow from Operations was HK$-0.05 Mil.
Total Receivables was HK$17.12 Mil.
Revenue was HK$28.29 Mil.
Gross Profit was HK$18.89 Mil.
Total Current Assets was HK$59.66 Mil.
Total Assets was HK$74.15 Mil.
Property, Plant and Equipment(Net PPE) was HK$9.23 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$3.51 Mil.
Selling, General, & Admin. Expense(SGA) was HK$20.94 Mil.
Total Current Liabilities was HK$10.92 Mil.
Long-Term Debt & Capital Lease Obligation was HK$0.07 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(15.025 / 26.939) / (17.118 / 28.286)
=0.557742 / 0.605176
=0.9216

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(18.888 / 28.286) / (17.602 / 26.939)
=0.667751 / 0.653402
=1.022

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (58.447 + 10.659) / 71.44) / (1 - (59.658 + 9.233) / 74.152)
=0.032671 / 0.070949
=0.4605

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=26.939 / 28.286
=0.9524

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.506 / (3.506 + 9.233)) / (3.477 / (3.477 + 10.659))
=0.275218 / 0.245968
=1.1189

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(20.225 / 26.939) / (20.943 / 28.286)
=0.75077 / 0.740402
=1.014

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.287 + 14.324) / 71.44) / ((0.066 + 10.923) / 74.152)
=0.218519 / 0.148196
=1.4745

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-6.324 - 0 - -0.053) / 71.44
=-0.08778

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Huakang Biomedical Holdings Co has a M-score of -3.36 suggests that the company is unlikely to be a manipulator.


Huakang Biomedical Holdings Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Huakang Biomedical Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.
Executives
Arena Investment Management (singapore) Pte Ltd 2102 Investment manager
Arena Investors, Lp 2102 Investment manager
Arena Sg Spv I, Llc 2201 Interest of corporation controlled by you
Tgga, Llc 2106 Person having a security interest in shares
Lau Lai Yee 2201 Interest of corporation controlled by you
Kokusai Resources Company Limited 2101 Beneficial owner
Zhang Shuguang 2101 Beneficial owner
Crystal Grant Limited 2101 Beneficial owner
Chang Yim Yang 2401 A concert party to an agreement to buy shares
Ever Charming Inc. 2101 Beneficial owner
Wealthy Pride Investment Limited 2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines